Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 13
2021 17
2022 22
2023 10
2024 13
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
National Institutes of Health COVID-19 Treatment Guidelines Panel: Perspectives and Lessons Learned.
Gulick RM, Pau AK, Daar E, Evans L, Gandhi RT, Tebas P, Ridzon R, Masur H, Lane HC; NIH COVID-19 Treatment Guidelines Panel; Adimora AA, Baker J, Kreuziger LB, Bedimo R, Belperio P, Bhalla A, Burgess T, Campbell D, Cantrill S, Chew K, Chiotos K, Coopersmith C, Davey R, Dzierba A, Eisnor D, Eschenauer G, Francis J, Gallagher J, Glidden D, Goldenberg N, Grund B, Han A, Hardy E, Harrison C, Henderson L, Higgs E, Hinkson C, Hughes B, Johnson S, Keller M, Kim A, Knight R, Kuriakose S, Lennox J, Lerner A, Levy M, Li J, MacBrayne C, Martin G, Nadig N, Nason M, Patel P, Pavia A, Proschan M, Schulert G, Seam N, Sheikh V, Simpson S, Singh K, Swindells S, Tien P, Uyeki T, Waghmare A, Wolfe C, Yazdany J, Aberg J. Gulick RM, et al. Among authors: waghmare a. Ann Intern Med. 2024 Nov;177(11):1547-1557. doi: 10.7326/ANNALS-24-00464. Epub 2024 Oct 1. Ann Intern Med. 2024. PMID: 39348691 Free article.
DESCRIPTION: In March 2020, the White House Coronavirus Task Force determined that clinicians in the United States needed expert treatment guidelines to optimally manage patients with COVID-19, a potentially life-threatening disease caused by a new pathogen for whic …
DESCRIPTION: In March 2020, the White House Coronavirus Task Force determined that clinicians in the United States needed expert treatment g …
SARS-CoV-2 Infection and COVID-19 in Children.
Waghmare A, Hijano DR. Waghmare A, et al. Clin Chest Med. 2023 Jun;44(2):359-371. doi: 10.1016/j.ccm.2022.11.014. Epub 2022 Nov 22. Clin Chest Med. 2023. PMID: 37085225 Free PMC article. Review.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is common in children, and clinical manifestations can vary depending on age, underlying disease, and vaccination status. ...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is common in children, and clinical manifestatio …
SARS-CoV-2 Infection and COVID-19 in Children.
Waghmare A, Hijano DR. Waghmare A, et al. Rheum Dis Clin North Am. 2025 Feb;51(1):139-156. doi: 10.1016/j.rdc.2024.09.003. Rheum Dis Clin North Am. 2025. PMID: 39550102 Review.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is common in children, and clinical manifestations can vary depending on age, underlying disease, and vaccination status. ...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is common in children, and clinical manifestatio …
Mucormycosis and COVID-19: An epidemic within a pandemic in India.
Selarka L, Sharma S, Saini D, Sharma S, Batra A, Waghmare VT, Dileep P, Patel S, Shah M, Parikh T, Darji P, Patel A, Goswami G, Shah A, Shah S, Lathiya H, Shah M, Sharma P, Chopra S, Gupta A, Jain N, Khan E, Sharma VK, Sharma AK, Chan ACY, Ong JJY. Selarka L, et al. Among authors: waghmare vt. Mycoses. 2021 Oct;64(10):1253-1260. doi: 10.1111/myc.13353. Epub 2021 Jul 24. Mycoses. 2021. PMID: 34255907 Free PMC article.
IMPORTANCE: Coronavirus disease (COVID-19) causes an immunosuppressed state and increases risk of secondary infections like mucormycosis. ...RESULTS: Of the 2567 COVID-19 patients admitted to 3 tertiary centres, 47 (1.8%) were diagnosed with mucormycos …
IMPORTANCE: Coronavirus disease (COVID-19) causes an immunosuppressed state and increases risk of secondary infections like mu …
Acute and Postacute COVID-19 Outcomes Among Immunologically Naive Adults During Delta vs Omicron Waves.
Doll MK, Waghmare A, Heit A, Levenson Shakoor B, Kimball LE, Ozbek N, Blazevic RL, Mose L, Boonyaratanakornkit J, Stevens-Ayers TL, Cornell K, Sheppard BD, Hampson E, Sharmin F, Goodwin B, Dan JM, Archie T, O'Connor T, Heckerman D, Schmitz F, Boeckh M, Crotty S. Doll MK, et al. Among authors: boeckh m, waghmare a. JAMA Netw Open. 2023 Feb 1;6(2):e231181. doi: 10.1001/jamanetworkopen.2023.1181. JAMA Netw Open. 2023. PMID: 36853602 Free PMC article.
OBJECTIVES: To examine COVID-19 acute and postacute clinical outcomes among a well-characterized cohort of unvaccinated and previously uninfected adults who contracted SARS-CoV-2 during the Omicron (BA.1/BA.2) surge, and to compare outcomes with …
OBJECTIVES: To examine COVID-19 acute and postacute clinical outcomes among a well-characterized cohort of unvaccinated and pr …
Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections.
Boonyaratanakornkit J, Boeckh M, Waghmare A. Boonyaratanakornkit J, et al. Among authors: boeckh m, waghmare a. Curr Opin Infect Dis. 2022 Aug 1;35(4):280-287. doi: 10.1097/QCO.0000000000000846. Epub 2022 Jul 5. Curr Opin Infect Dis. 2022. PMID: 35849517 Review.
Several novel mAbs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have received emergency use authorization by the Food and Drug Administration (FDA) for the early treatment of mild to moderate COVID-19. ...Novel mAbs are a …
Several novel mAbs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have received emergency use aut …
Clinical Profile of SARS-CoV-2-Infected Neonates.
Kulkarni RK, Valvi C, Dawre R, Rajput U, Nagpal R, Deshmukh I, Kamath P, Harwani R, Srinivasarangan R, Sonteke S, R A, Kamble S, Naik S, Bhosale R, Waghmare R, Modi D, Gajbhiye R, Kinikar AA. Kulkarni RK, et al. Among authors: waghmare r. Cureus. 2022 Jun 24;14(6):e26298. doi: 10.7759/cureus.26298. eCollection 2022 Jun. Cureus. 2022. PMID: 35898362 Free PMC article.
Background There are conflicting data on the mother-to-child transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and few studies have described the clinical course of neonates infected with SARS-CoV-2. Objectives …
Background There are conflicting data on the mother-to-child transmission of severe acute respiratory syndrome coronavirus 2 (SARS- …
Sphingolipids: Effectors and Achilles Heals in Viral Infections?
Schneider-Schaulies S, Schumacher F, Wigger D, Schöl M, Waghmare T, Schlegel J, Seibel J, Kleuser B. Schneider-Schaulies S, et al. Among authors: waghmare t. Cells. 2021 Aug 24;10(9):2175. doi: 10.3390/cells10092175. Cells. 2021. PMID: 34571822 Free PMC article. Review.
Acute and Post-Acute COVID-19 Outcomes Among Immunologically Naive Adults During Delta Versus Omicron Waves.
Doll MK, Waghmare A, Heit A, Levenson Shakoor B, Kimball LE, Ozbek N, Blazevic RL, Mose L, Boonyaratanakornkit J, Stevens-Ayers TL, Cornell K, Sheppard BD, Hampson E, Sharmin F, Goodwin B, Dan JM, Archie T, O'Connor T, Heckerman D, Schmitz F, Boeckh M, Crotty S. Doll MK, et al. Among authors: boeckh m, waghmare a. medRxiv [Preprint]. 2022 Nov 14:2022.11.13.22282222. doi: 10.1101/2022.11.13.22282222. medRxiv. 2022. Update in: JAMA Netw Open. 2023 Feb 1;6(2):e231181. doi: 10.1001/jamanetworkopen.2023.1181. PMID: 36425923 Free PMC article. Updated. Preprint.
OBJECTIVE: To examine COVID-19 acute and post-acute clinical outcomes among a well-characterized cohort of unvaccinated and previously uninfected adults who contracted SARS-CoV-2 during the Omicron (BA.1/BA.2) surge, and to compare outcomes with …
OBJECTIVE: To examine COVID-19 acute and post-acute clinical outcomes among a well-characterized cohort of unvaccinated and pr …
Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
Khawaja F, Papanicolaou G, Dadwal S, Pergam SA, Wingard JR, Boghdadly ZE, Abidi MZ, Waghmare A, Shahid Z, Michaels L, Hill JA, Kamboj M, Boeckh M, Auletta JJ, Chemaly RF. Khawaja F, et al. Among authors: boeckh m, waghmare a. Transplant Cell Ther. 2023 Jan;29(1):10-18. doi: 10.1016/j.jtct.2022.10.010. Epub 2022 Oct 21. Transplant Cell Ther. 2023. PMID: 36273782 Free PMC article.
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), disproportionately affects immunocompromised and elderly patients. ...Optimizing the use, timing, and number of doses of the COVID …
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 …
74 results